Home Newsfeeds Goldman Sachs Maintains Sell on JinkoSolar Holding Co, Raises Price Target to $35

Goldman Sachs Maintains Sell on JinkoSolar Holding Co, Raises Price Target to $35

Goldman Sachs analyst Brian Lee maintains JinkoSolar Holding Co (NYSE:JKS) with a Sell and raises the price target from $31 to $35.

byBenzinga Newsdesk

August 29, 2022

1 minute read

Goldman Sachs analyst Brian Lee maintains JinkoSolar Holding Co (NYSE:JKS) with a Sell and raises the price target from $31 to $35.

Evaluating Microsoft Against Peers In Software Industry

By Benzinga Insights

May 13, 11:00 AM

In today’s fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze…

MSFT

Recap: Watsco Q2 Earnings

By Benzinga Insights

July 26, 8:37 AM

Watsco (NYSE:WSO) reported its Q2 earnings results on Tuesday, July 26, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

WSO

M&A
News

Manulife Financial Corp’s Manulife Investment Management Completes Acquisition of Multi-Sector Alternative Credit Manager CQS, Financial Terms Remain Undisclosed

By Benzinga Newsdesk

April 3, 4:44 AM

Manulife Investment Management announced today it has closed on the previously announced agreement to acquire multi-sector alternative credit manager CQS. Regulatory approval for this transaction was received

MFC

French Pharma Giant Sanofi’s Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs

By Vandana Singh

February 1, 10:24 AM

Sanofi reports Q4 operating income of €2.6B, down 5.2%. Revenues rise 1.8% to €10.92B, Specialty Care grows 13.7%, Dupixent sales surge.

SNY

Goldman Sachs Maintains Sell on JinkoSolar Holding Co, Raises Price Target to $35

Related Posts

Evaluating Microsoft Against Peers In Software Industry

Recap: Watsco Q2 Earnings

Manulife Financial Corp’s Manulife Investment Management Completes Acquisition of Multi-Sector Alternative Credit Manager CQS, Financial Terms Remain Undisclosed

French Pharma Giant Sanofi’s Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs